Colorectal Cancer | Clinical

Health-Related Quality of Life Low in Younger Colorectal Cancer Survivors

January 18, 2021

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

TAS-102 Shows OS Benefit With Bevacizumab in mCRC Ineligible for Intensive Therapy

January 17, 2021

The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.

Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL

January 16, 2021

The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

January 15, 2021

Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.

Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC

January 15, 2021

Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.

New CRC Screening Recommendations Posted for Adults Aged 45 to 75 Years

October 30, 2020

A draft recommendation statement was published by the United States Preventive Services Task Force stating that screening for colorectal cancer should start at the age of 45, according to a press release from the Task Force Bulletin.

3-Month CAPOX Regimen Appears Less Toxic Than 6-Month Treatment in CRC

October 30, 2020

Results of a randomized phase 3 trial demonstrated that the 3-month regimen of adjuvant combination therapy caused significantly less grade 2 or more peripheral sensory neuropathy than the 6-month regimen as treatment of patients with high-risk stage II colorectal cancer, while not affecting the 3-year disease-free survival rate, according to a report in the Annals of Oncology.